Jeremy Hwang, MD
Ophthalmology · West Hartford, CTNPI 1841581154
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,330 of the $5,943 with a category attached, or 89.7%. 24 manufacturers reported payments, led by AbbVie at 39.6% of the total.
Across 247 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novartis$579
- Bausch & Lomb Americas Inc.$494
- Oyster Point Pharma, Inc.$454
- Kala Pharmaceuticals, Inc.$418
- Rxsight Inc$322
- plus $1K from 18 others
What the payments were for
- Grants$5008%
- Food & beverage$5,33090%
- Education$1132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $2,355 |
| Novartis | 28 | $579 |
| Bausch & Lomb Americas Inc. | 28 | $494 |
| Oyster Point Pharma, Inc. | 17 | $454 |
| Kala Pharmaceuticals, Inc. | 22 | $418 |
| Rxsight Inc | 4 | $322 |
| Sun Pharmaceutical Industries Inc. | 17 | $282 |
| Aerie Pharmaceuticals, Inc. | 10 | $243 |
| Alcon | 9 | $184 |
| Dompe US, Inc. | 3 | $81 |
| Apellis Pharmaceuticals, Inc. | 2 | $63 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $62 |
| Amgen | 3 | $58 |
| Ivantis, Inc | 3 | $57 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $48 |
| Shire North American Group Inc | 3 | $43 |
| Harrow Eye, LLC | 2 | $40 |
| Tarsus Pharmaceuticals, Inc. | 2 | $36 |
| Sandoz | 1 | $32 |
| Thea Pharma Inc. | 1 | $20 |
| Glaukos Corporation | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,943 in reported general payments places this provider in the 85th percentile of 279 ophthalmology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 395 | $272,246 |
| RocklatanNetarsudil Mesylat/Latanoprost | 287 | $163,275 |
| RestasisCyclosporine | 101 | $121,689 |
| RhopressaNetarsudil Mesylate | 235 | $121,004 |
| VyzultaLatanoprostene Bunod | 179 | $104,858 |
| CombiganBrimonidine Tartrate/Timolol | 155 | $82,675 |
| ProlensaBromfenac Sodium | 213 | $76,417 |
| Prednisolone Acetate | 937 | $58,040 |
| XiidraLifitegrast | 44 | $57,324 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 289 | $46,397 |
| Alphagan PBrimonidine Tartrate | 84 | $41,097 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 173 | $40,583 |
| Bromfenac Sodium | 171 | $39,486 |
| Travoprost | 164 | $29,451 |
| Brimonidine Tartrate | 349 | $28,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,355 | $517,707735 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $243 | $284,279522 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $494 | $177,471243 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $48 | $78,013228 claims |
| AlconSimbrinza, Azopt | $184 | $45,822184 claims |
| NovartisIlevro | $579 | $4,44612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 279 ophthalmology providers in Connecticut.
Other ophthalmology in West Hartford
- Alan SolinskyWest Hartford$13K
- David JengWest Hartford$7K
- Christopher OrrWest Hartford$7K
- Lyndon LeeWest Hartford$7K
- Neeru DuaWest Hartford$4K
- John HuangHartford$267K
- Amir CohenNew Haven$266K
- James MurphyHamden$176K
- James TalbotNew Canaan$47K
- Paul KangNew Haven$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.